Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide nebuliser versus budesonide nasal rinse for chronic rhinosinusitis
ACTRN12620000578909Phase 2Not yet recruiting
- Sponsor
- Professor Peter-John Wormald
- Start
- May 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of budesonide in chronic rhinosinusitis (CRS) (2 arms), sponsored by Professor Peter-John Wormald. Primary endpoints: Change in Lund-Kennedy Endoscopic Score, Change in Sino-nasal Outcome Test 22 score and 1 more. Planned start May 2020; status: not yet recruiting.
02
Drugs
budesonide
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on ACTRN12620000578909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000578909.